Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Aligos Therapeutics Price-to-Tangible-Book Related Terms
Aligos Therapeutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Aligos Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALGS vs KPTI, EDSA, FLNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Aligos Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Aligos Therapeutics (ALGS) has a Price-to-Tangible-Book of 0.98 as of Sep. 15, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Aligos Therapeutics and its competitors. According to the industry distribution chart, Aligos Therapeutics ranks #140 out of 1135 companies in the Biotechnology industry, placing it in the top 12.3%.
Is Aligos Therapeutics' Price-to-Tangible-Book too high?
Aligos Therapeutics' current Price-to-Tangible-Book is 0.98. The Biotechnology industry median Price-to-Tangible-Book is 3.31. Aligos Therapeutics' value of 0.98 is 70.4% below this industry median. Based on the distribution chart, Aligos Therapeutics ranks #140 out of 1135 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aligos Therapeutics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' Price-to-Tangible-Book compare to KPTI and EDSA?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #140 out of 1135 companies for Price-to-Tangible-Book. This places Aligos Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 3.31. Aligos Therapeutics' value of 0.98 is 70.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.31, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aligos Therapeutics's current Price-to-Tangible-Book of 0.98 is 70.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Aligos Therapeutics and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aligos Therapeutics's current Price-to-Tangible-Book is 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Possible Value Trap. The stock's GF Value™ is $33.91, compared to a current price of $5.00 — trading 85.3% below its estimated fair value. The current Price-to-Tangible-Book is 0.98 and 70.4% below the Biotechnology industry median of 3.31. Aligos Therapeutics' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current Price-to-Tangible-Book is 0.98 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be undervalued.
The current stock price of $5.00 is trading 85.3% below its estimated GF Value™ of $33.91.
GuruFocus considers Aligos Therapeutics to be Possible Value Trap.
Key valuation signals for ALGS:
Price-to-Tangible-Book: 0.98
GF Value™: $33.91 vs. price of $5.00 (85.3% below fair value)
Industry Position: 70.4% below the Biotechnology median (#140 of 1135)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
43GF Score
Get the complete analysis for ALGS
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
